PSMA PET/CT Biopsy Enhances Detection of Prostate Cancer

PSMA PET/CT-targeted biopsy has been found to detect clinically significant prostate cancers in 37 percent of men with negative or inconclusive MRI findings, as opposed to a 21 percent detection rate using systematic biopsy alone. This combined approach raises the detection rate to 41 percent, according to new research published in the September issue of The Journal of Nuclear Medicine.

The study investigated whether PSMA PET/CT-guided targeted biopsy and semiquantitative PET parameters could improve cancer detection in men who present persistent clinical risk factors despite negative MRI results. Current prostate cancer diagnostic methods primarily involve systematic or image-guided biopsies, with multiparametric MRI often serving as the key tool for detection and localization of significant disease.

However, it is noted that up to 20-30 percent of substantial prostate cancer cases may be overlooked in patients with non-diagnostic MRI findings. Andrea Farolfi, MD, from the IRCCS Azienda Ospedaliero-Universitaria di Bologna, emphasized the importance of these findings, indicating that negative MRI results do not eliminate the possibility of clinically significant prostate cancer, which can lead to unnecessary repeat biopsies while tumors remain undetected.

The study included 63 men, all of whom underwent 68Ga-PSMA-11 PET/CT followed by PET fusion-guided prostate biopsy, with a subset undergoing dynamic total-body PET analysis. Positive PSMA PET/CT results were noted in 25 out of 26 patients diagnosed with clinically significant prostate cancer. Combination biopsy methods yielded a substantially higher rate of detection compared to either method alone. Notably, the PSMA SUVmax value was independently linked to the presence of clinically significant disease, while dynamic total-body PET showcased unique kinetic patterns in aggressive tumors.

Farolfi stated, "Our findings suggest that PSMA PET/CT could provide an additional tool for identifying men who remain at risk despite non-diagnostic MRI findings and for directing the biopsy toward the most suspicious area."

The research is titled "PSMA PET/CT–Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study" and is conducted by a team from the IRCCS Azienda Ospedaliero-Universitaria di Bologna, among others. The implications of this study have the potential to refine risk stratification and guide biopsy in challenging diagnostic populations, ultimately reducing the risk of missed cancers and unnecessary interventions.